Immunome (IMNM) Stock Forecast & Price Target

Immunome is supported by a compelling late-stage signal in varegacestat, where RINGSIDE showed an 84% reduction in risk of progression or death, 55.7% ORR, and durable 1-/2-year PFS of 94%/89% versus 66%/57% on placebo, strengthening the case for approval ahead of the April 28, 2027 PDUFA. The company also appears differentiated by its broader pipeline, with IM-1021 offering a potentially best-in-class ROR1 ADC thesis built around the HC74 payload’s low-efflux, high-permeability profile and a DAR of 8, while IM-3050 and multiple preclinical ADCs add additional shots on goal. This mix of de-risked clinical efficacy, near-term catalysts in 2026, and a platform aimed at overcoming ADC resistance supports a constructive fundamental outlook.

Immunome is challenged by fundamental target-risk in ROR1, because ROR1 is not an oncogene, is not required for cancer cell viability, and Broad Institute DepMap CRISPR data across 1,200+ cell lines suggest knockout has no meaningful impact on growth or survival, supporting antigen downregulation as a plausible escape route for ADCs. The lack of a reliable biomarker is another major weakness: expression appears weakly correlated with surface-accessible target density, mRNA does not ensure functional cell-surface localization, and there is no validated IHC or RNA selection tool to identify likely responders with confidence. Clinical evidence for zilovertamab vedotin in solid tumors is also unfavorable, with roughly one responder out of 100+ participants across varied histologies and equivocal Merck data, leaving little rationale for further ROR1 investment.